ABSTRACT
Rickets results from impaired mineralization of growing bone due to alterations in calcium and phosphate homeostasis. Clinical signs of rickets are related to the age of the patient, the duration of the disease, and the underlying disorder. The most common signs of rickets are swelling of the wrists, knees or ankles, bowing of the legs (knock-knees, outward bowing, or both) and inability to walk. However, clinical features alone cannot differentiate between the various forms of rickets. Rickets includes a heterogeneous group of acquired and inherited diseases. Nutritional rickets is due to a deficiency of vitamin D, dietary calcium or phosphate. Mutations in genes responsible for vitamin D metabolism or function, the production or breakdown of fibroblast growth factor 23, renal phosphate regulation, or bone mineralization can lead to the hereditary form of rickets. This position paper reviews the relevant literature and presents the expertise of the Bone and Mineral Metabolism Group of the Italian Society of Pediatric Endocrinology and Diabetology (SIEDP). The aim of this document is to provide practical guidance to specialists and healthcare professionals on the main criteria for diagnosis, treatment, and management of patients with rickets. The various forms of rickets are discussed, and detailed references for the discussion of each form are provided. Algorithms to guide the diagnostic approach and recommendations to manage patients with rare forms of hereditary rickets are proposed.
Subject(s)
Endocrinology , Rickets , Humans , Rickets/diagnosis , Rickets/therapy , Rickets/metabolism , Endocrinology/methods , Endocrinology/standards , Italy , Vitamin D/metabolism , Vitamin D/therapeutic use , Child , Societies, Medical/standards , Disease ManagementABSTRACT
The definition of "Vitamin D" encompasses a group of fat-soluble steroid compounds of different origins with similar chemical structures and the same biological effects. Vitamin D deficiency and/or a defect in the process of its synthesis or transport predispose individuals to several types of rickets. In addition to cholecalciferol, ergocalciferol, and vitamins D3 and D2, there are also active metabolites for the treatment of this condition which are commercially available. Calcitriol and aphacalcidiol are active metabolites that do not require the renal activation step, which is required with calcifediol, or hepatic activation. The purpose of this review is to summarize current approaches to the treatment of rickets for generalist physicians, focusing on the best vitamin D form to be used in each type, or, in the case of X-linked hypophosphatemic rickets (XLH), on both conventional and innovative monoclonal antibody treatments.
Subject(s)
Familial Hypophosphatemic Rickets , Rickets , Humans , Vitamin D/therapeutic use , Rickets/drug therapy , Rickets/metabolism , Calcitriol/therapeutic use , Cholecalciferol/therapeutic use , Cholecalciferol/metabolism , Familial Hypophosphatemic Rickets/drug therapy , Familial Hypophosphatemic Rickets/metabolism , VitaminsABSTRACT
Exclusive breastfeeding is considered the ideal food in the first six months of life; however, paradoxically, vitamin D content in human breast milk is clearly low and insufficient to obtain the recommended intake of 400 IU daily. This article summarizes the extraordinary metabolism of vitamin D during pregnancy and its content in human breast milk. The prevalence of hypovitaminosis D in pregnant women and/or nursing mothers and its potential maternal-fetal consequences are analyzed. The current guidelines for vitamin D supplementation in pregnant women, nursing mothers, and infants to prevent hypovitaminosis D in breastfed infants are detailed. Low vitamin D content in human breast milk is probably related to active changes in human lifestyle habits (reduced sunlight exposure).
Subject(s)
Rickets , Vitamin D Deficiency , Infant , Female , Humans , Pregnancy , Vitamin D/therapeutic use , Vitamin D/metabolism , Breast Feeding , Dietary Supplements , Vitamins/metabolism , Vitamin D Deficiency/epidemiology , Vitamin D Deficiency/prevention & control , Vitamin D Deficiency/metabolism , Rickets/metabolism , Milk, Human/metabolismABSTRACT
Active vitamin D form 1α,25-dihydroxtvitamin D3 (1,25(OH)2D3) plays pivotal roles in calcium homeostasis and osteogenesis via its transcription regulation effect via binding to vitamin D receptor (VDR). Mutated VDR often causes hereditary vitamin D-dependent rickets (VDDR) type II, and patients with VDDR-II are hardly responsive to physiological doses of 1,25(OH)D3. Current therapeutic approaches, including high doses of oral calcium and supraphysiologic doses of 1,25(OH)2D3, have limited success and fail to improve the quality of life of affected patients. Thus, various vitamin D analogues have been developed as therapeutic options. In our previous study, we generated genetically modified rats with mutated Vdr(R270L), an ortholog of human VDR(R274L) isolated from the patients with VDDR-II. The significant reduced affinity toward 1,25(OH)2D3 of rat Vdr(R270L) enabled us to evaluate biological activities of exogenous VDR ligand without 1α-hydroxy group such as 25(OH)D3. In this study, 2α-[2-(tetrazol-2-yl)ethyl]-1α,25(OH)2D3 (AH-1) exerted much higher affinity for Vdr(R270L) in in vitro ligand binding assay than both 25(OH)D3 and 1,25(OH)2D3. A robust osteogenic activity of AH-1 was observed in Vdr(R270L) rats. Only a 40-fold lower dose of AH-1 than that of 25(OH)D3 was effective in ameliorating rickets symptoms in Vdr(R270L) rats. Therefore, AH-1 may be promising for the therapy of VDDR-II with VDR(R274L).
Subject(s)
Receptors, Calcitriol , Rickets , Animals , Calcium , Humans , Ligands , Osteogenesis , Quality of Life , Rats , Receptors, Calcitriol/genetics , Receptors, Calcitriol/metabolism , Rickets/metabolism , Vitamin DABSTRACT
We have developed an in vitro system to easily examine the affinity for vitamin D receptor (VDR) and CYP24A1-mediated metabolism as two methods of assessing vitamin D derivatives. Vitamin D derivatives with high VDR affinity and resistance to CYP24A1-mediated metabolism could be good therapeutic agents. This system can effectively select vitamin D derivatives with these useful properties. We have also developed an in vivo system including a Cyp27b1-gene-deficient rat (a type I rickets model), a Vdr-gene-deficient rat (a type II rickets model), and a rat with a mutant Vdr (R270L) (another type II rickets model) using a genome editing method. For Cyp27b1-gene-deficient and Vdr mutant (R270L) rats, amelioration of rickets symptoms can be used as an index of the efficacy of vitamin D derivatives. Vdr-gene-deficient rats can be used to assess the activities of vitamin D derivatives specialized for actions not mediated by VDR. One of our original vitamin D derivatives, which displays high affinity VDR binding and resistance to CYP24A1-dependent metabolism, has shown good therapeutic effects in Vdr (R270L) rats, although further analysis is needed.
Subject(s)
Drug Discovery , Vitamin D , Animals , Drug Evaluation, Preclinical , Humans , Rats , Rickets/drug therapy , Rickets/genetics , Rickets/metabolism , Vitamin D/analogs & derivatives , Vitamin D/pharmacokinetics , Vitamin D/therapeutic useSubject(s)
Osteogenesis/physiology , Rickets/epidemiology , Rickets/prevention & control , Vitamin D/administration & dosage , Child , Humans , Osteogenesis/drug effects , Rickets/metabolism , Treatment Outcome , Vitamin D Deficiency/epidemiology , Vitamin D Deficiency/metabolism , Vitamin D Deficiency/prevention & controlABSTRACT
Recent studies have suggested that vitamin D activities involve vitamin D receptor (VDR)-dependent and VDR-independent effects of 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) and 25-hydroxyvitamin D3 (25(OH)D3) and ligand-independent effects of the VDR. Here, we describe a novel in vivo system using genetically modified rats deficient in the Cyp27b1 or Vdr genes. Type II rickets model rats with a mutant Vdr (R270L), which recognizes 1,25(OH)2D3 with an affinity equivalent to that for 25(OH)D3, were also generated. Although Cyp27b1-knockout (KO), Vdr-KO, and Vdr (R270L) rats each showed rickets symptoms, including abnormal bone formation, they were significantly different from each other. Administration of 25(OH)D3 reversed rickets symptoms in Cyp27b1-KO and Vdr (R270L) rats. Interestingly, 1,25(OH)2D3 was synthesized in Cyp27b1-KO rats, probably by Cyp27a1. In contrast, the effects of 25(OH)D3 on Vdr (R270L) rats strongly suggested a direct action of 25(OH)D3 via VDR-genomic pathways. These results convincingly suggest the usefulness of our in vivo system.
Subject(s)
Receptors, Calcitriol/genetics , Receptors, Calcitriol/metabolism , Vitamin D/metabolism , 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/genetics , Animals , Calcifediol/genetics , Calcifediol/metabolism , Calcitriol/pharmacology , Disease Models, Animal , Male , Rats , Rats, Wistar , Rickets/metabolism , Vitamin D/analogs & derivatives , Vitamin D/genetics , Vitamin D3 24-Hydroxylase/geneticsABSTRACT
CONTEXT: Hypophosphatemic rickets (HR) is a group of rare hereditary renal phosphate wasting disorders caused by mutations in PHEX, FGF23, DMP1, ENPP1, CLCN5, SLC9A3R1, SLC34A1, or SLC34A3. OBJECTIVE: A large kindred with 5 HR patients was recruited with dominant inheritance. The study was undertaken to investigate underlying genetic defects in HR patients. DESIGN: Patients and their family members were initially analyzed for PHEX and FGF23 mutations using polymerase chain reaction sequencing and copy number analysis. Exome sequencing was subsequently performed to identify novel candidate genes. RESULTS: PHEX and FGF23 mutations were not detected in the patients. No copy number variation was observed in the genome using CytoScan HD array analysis. Mutations in DMP1, ENPP1, CLCN5, SLC9A3R1, SLC34A1, or SLC34A3 were also not found by exome sequencing. A novel c.979-96 T>A mutation in the SGK3 gene was found to be strictly segregated in a heterozygous pattern in patients and was not present in normal family members. The mutation is located 1 bp downstream of a highly conserved adenosine branch point, resulted in exon 13 skipping and in-frame deletion of 29 amino acids, which is part of the protein kinase domain and contains a Thr-320 phosphorylation site that is required for its activation. Protein tertiary structure modelling showed significant structural change in the protein kinase domain following the deletion. CONCLUSIONS: The c.979-96 T>A splice mutation in the SGK3 gene causes exon 13 skipping and deletion of 29 amino acids in the protein kinase domain. The SGK3 mutation may cause autosomal dominant HR.
Subject(s)
Familial Hypophosphatemic Rickets/etiology , Mutation , Phosphates/metabolism , Protein Serine-Threonine Kinases/genetics , Rickets/etiology , Adult , Biomarkers/analysis , Child , Child, Preschool , DNA Mutational Analysis , Familial Hypophosphatemic Rickets/metabolism , Familial Hypophosphatemic Rickets/pathology , Female , Fibroblast Growth Factor-23 , Humans , Kidney/metabolism , Kidney/pathology , Male , Middle Aged , Pedigree , Prognosis , Rickets/metabolism , Rickets/pathologyABSTRACT
Rickets was first described in great detail in the mid 17th century and was affecting a great number of children in major European cities. The disease, however, existed already in the Roman times. The etiology of this disease remained enigmatic until the 1920s when two different mechanisms, lack of exposure to sunlight and lack of a dietary factor were finally solved by the discovery of vitamin D and its dual origin. Soon thereafter, the implementation of vitamin D supplementation for all infants and small children largely eliminated nutritional rickets in Europe and North America. It took nearly a century to elucidate the complex chemistry, metabolism, mode and spectrum of activity of the vitamin D endocrine system. Nutritional rickets, whether due to simple vitamin D or calcium deficiency or both, remains widely ravaging many infants and children around the world. Asian countries and the Middle East are mainly confronted with vitamin D deficiency whereas many African and some Asian countries face calcium deficiency rickets. Immigrants and refugees or in general people with a darker skin living in moderate climate zone are also confronted with this disease. There is great consensus how this disease could be prevented or cured. In collaboration with most international professional societies, we prepare a memorandum, in line with the successful battle against iodine deficiency disorders, to convince the World Health Organization and its member states to start an implementation program to eradicate nutritional rickets by 2030.
Subject(s)
Rickets/etiology , Rickets/prevention & control , Vitamin D/therapeutic use , Vitamins/therapeutic use , Calcium/metabolism , History, 17th Century , History, 18th Century , History, 19th Century , History, 20th Century , History, 21st Century , Humans , Rickets/history , Rickets/metabolism , Vitamin D/metabolism , Vitamin D Deficiency/complications , Vitamin D Deficiency/metabolism , Vitamin D Deficiency/prevention & control , Vitamins/metabolism , World Health OrganizationABSTRACT
The aim of this article is to correct a very general error in scientific articles, in textbooks and in the Internet that has become an accepted fact. In this literature, the term "vitamin Eâ³ is used for several similar molecules (both tocopherols and tocotrienols) that have never been shown to have vitamin property, i.e. a protective effect against the human deficiency disease. In fact, the name "vitamin Eâ³ should only be used to define molecules that prevent the human deficiency disease "Ataxia with Vitamin E Deficiency" (AVED). Only one such molecule is known, α-tocopherol. This error may confuse consumers as well as medical doctors, who prescribe vitamin E without realizing that the current use of the name includes molecules of unknown, if not unwanted functions.
Subject(s)
Antioxidants/administration & dosage , Ataxia/diet therapy , Dietary Supplements , Rickets/diet therapy , Scurvy/diet therapy , Vitamin E Deficiency/diet therapy , Ascorbic Acid/administration & dosage , Ataxia/metabolism , Ataxia/physiopathology , Ataxia/prevention & control , Calcitriol/administration & dosage , Humans , Rickets/metabolism , Rickets/physiopathology , Rickets/prevention & control , Scurvy/metabolism , Scurvy/physiopathology , Scurvy/prevention & control , Stereoisomerism , Terminology as Topic , Tocotrienols/chemistry , Tocotrienols/classification , Vitamin E/administration & dosage , Vitamin E Deficiency/metabolism , Vitamin E Deficiency/physiopathology , Vitamin E Deficiency/prevention & control , alpha-Tocopherol/administration & dosageABSTRACT
Most bone formation and mineralization occurs late in gestation. Accretion of adequate minerals is a key element of this process and is often interrupted through preterm birth. In utero, mineral transport is accomplished via active transport across the placenta and does not require fetal hormone input. Postnatal mineral homeostasis requires a balance of actions of parathyroid hormone, calcitonin, and vitamin D on target organs. Preterm birth, asphyxia, acidosis, and prolonged parenteral nutrition increase the risk of mineral imbalance and metabolic bone disease (MBD). Aggressive postnatal nutrition is key to preventing and treating MBD in preterm infants.
Subject(s)
Bone Diseases, Metabolic/metabolism , Calcification, Physiologic , Calcitonin/metabolism , Calcium/metabolism , Parathyroid Hormone/metabolism , Phosphorus/metabolism , Vitamin D/metabolism , Acidosis/metabolism , Asphyxia Neonatorum/metabolism , Homeostasis , Humans , Infant, Newborn , Infant, Premature , Parenteral Nutrition , Rickets/metabolismABSTRACT
When an infant presents with X-rays showing multiple unexplained fractures in various stages of healing (MUFVSH), the child is usually diagnosed with child abuse based on criteria of the Academy of Pediatrics' Committee on Child Abuse and Neglect (AAPCCAAN). Almost always, the infant is subsequently removed from the home and civil or criminal proceeding commence. It may be that healing infantile rickets or other poorly understood metabolic bone disorders of infancy are responsible for these x-rays. Activated vitamin D is a seco-steroid hormone, whose mechanism of action is genetic regulation. Lack of it can result in musculoskeletal defects known as rickets. Low calcium can also cause rickets. However, it is clear that experts for the state believe that the x-rays in these cases are so definitive as to be pathognomonic for child abuse. Therefore, if the caregivers deny abusing their infants, experts following American Academy of Pediatric's Committee on Child Abuse and Neglect. guidelines are essentially claiming that x-rays showing multiple unexplained fractures in various stages of healing are lie detector tests. However, it is not widely appreciated that the gold standard for the diagnosis of rickets is a bone biopsy, not x-rays, as radiologists miss biopsy proven rickets 80% of the time; that is, 4 out of 5 infants with rickets will have normal x-rays. In this article we provide reports of two cases and their outcomes. We discuss information about healing infantile rickets and an example of common sense medical conclusions in these cases. This information could lead to a significant reduction in the number of innocent parents having their infant removed or sent to prison.
Subject(s)
Bone and Bones/diagnostic imaging , Child Abuse/diagnosis , Fractures, Bone/diagnostic imaging , Rickets/diagnostic imaging , Vitamin D/metabolism , Adult , Biopsy , Bone and Bones/drug effects , Bone and Bones/metabolism , Bone and Bones/pathology , Child , Diagnostic Errors , Fractures, Bone/diet therapy , Fractures, Bone/metabolism , Fractures, Bone/pathology , Humans , Infant , Male , Radiography , Rickets/diet therapy , Rickets/metabolism , Rickets/pathology , Vitamin D/administration & dosageABSTRACT
Vitamin D metabolism involves 3 highly specific cytochrome P450 (CYP) enzymes (25-hydroxylase, 1α-hydroxylase, and 24-hydroxylase) involved in the activation of vitamin D3 to the hormonal form, 1,25-(OH)2D3, and the inactivation of 1,25-(OH)2D3 to biliary excretory products. Mutations of the activating enzymes CYP2R1 and CYP27B1 cause lack of normal 1,25-(OH)2D3 synthesis and result in rickets whereas mutations of the inactivating enzyme CYP24A1 cause build-up of excess 1,25-(OH)2D3 and result in hypercalcemia, nephrolithiasis, and nephrocalcinosis. This article reviews the literature for 3 clinical conditions. Symptoms, diagnosis, treatment, and management of vitamin D-dependent rickets and idiopathic infantile hypercalcemia are discussed.
Subject(s)
Cholestanetriol 26-Monooxygenase/genetics , Cytochrome P450 Family 2/genetics , Hypercalcemia/genetics , Infant, Newborn, Diseases/genetics , Metabolism, Inborn Errors/genetics , Mutation , Rickets/genetics , Vitamin D3 24-Hydroxylase/genetics , Cholestanetriol 26-Monooxygenase/metabolism , Cytochrome P450 Family 2/metabolism , Humans , Hypercalcemia/diagnosis , Hypercalcemia/metabolism , Infant, Newborn, Diseases/diagnosis , Infant, Newborn, Diseases/metabolism , Metabolism, Inborn Errors/diagnosis , Metabolism, Inborn Errors/metabolism , Rickets/diagnosis , Rickets/metabolism , Vitamin D3 24-Hydroxylase/metabolismABSTRACT
Although the intestine plays the major role in 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] action on calcium homeostasis, the mechanisms involved remain incompletely understood. The established model of 1,25(OH)2D3-regulated intestinal calcium absorption postulates a critical role for the duodenum. However, the distal intestine is where 70% to 80% of ingested calcium is absorbed. To test directly the role of 1,25(OH)2D3 and the vitamin D receptor (VDR) in the distal intestine, three independent knockout (KO)/transgenic (TG) lines expressing VDR exclusively in the ileum, cecum, and colon were generated by breeding VDR KO mice with TG mice expressing human VDR (hVDR) under the control of the 9.5-kb caudal type homeobox 2 promoter. Mice from one TG line (KO/TG3) showed low VDR expression in the distal intestine (<50% of the levels observed in KO/TG1, KO/TG2, and wild-type mice). In the KO/TG mice, hVDR was not expressed in the duodenum, jejunum, kidney, or other tissues. Growth arrest, elevated parathyroid hormone level, and hypocalcemia of the VDR KO mice were prevented in mice from KO/TG lines 1 and 2. Microcomputed tomography analysis revealed that the expression of hVDR in the distal intestine of KO/TG1 and KO/TG2 mice rescued the bone defects associated with systemic VDR deficiency, including growth plate abnormalities and altered trabecular and cortical parameters. KO/TG3 mice showed rickets, but less severely than VDR KO mice. These findings show that expression of VDR exclusively in the distal intestine can prevent abnormalities in calcium homeostasis and bone mineralization associated with systemic VDR deficiency.
Subject(s)
Cecum/metabolism , Colon/metabolism , Genetic Therapy , Ileum/metabolism , Receptors, Calcitriol/genetics , Rickets/genetics , Rickets/therapy , Animals , Caco-2 Cells , Calcification, Physiologic/genetics , Calcium/metabolism , Cecum/pathology , Colon/pathology , Female , Genetic Therapy/methods , Humans , Ileum/pathology , Intestinal Absorption/genetics , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Receptors, Calcitriol/metabolism , Rickets/metabolism , Rickets/pathologyABSTRACT
PURPOSE: Rickets is a recurrent disease worldwide, especially in countries with limited resources (Nield et al Am Fam Physician 74(4):619-626, 2006; Thacher et al Ann Trop Paediatr 26(1):1-16, 2006). Medical therapy including orally administered calcium substitution is shown to improve a patients clinical symptoms and positively impact bone deformities, especially in the lower extremity. Even though orthopaedic intervention is necessary in a significant percentage of patients, few reports exist about operative deformity correction in patients wtih rickets. METHODS: We describe our concept of operative treatment by single-stage, three-dimensional closing-wedge osteotomies on 45 deformed legs in 27 patients from the rural area of Kaduna, North Nigeria, with calcium-deficiency rickets and evaluate the early results in a 1.5-year follow-up. RESULTS: We found a significant improvement in parameters of quality of life, functionality, clinical and radiological angulation and angles following the definition of Paley et al., with a complication rate of 4 % under 88 osteotomies (Paley et al Orthop Clin North Am 25(3):425-65, 1994). CONCLUSION: The described operative therapy shows to be sufficient and with satisfactory results in correcting rickets-related leg deformities under rural circumstances with low availability of medical resources.
Subject(s)
Calcium/deficiency , Leg Bones/surgery , Osteotomy/methods , Rickets/surgery , Adolescent , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Male , Nigeria , Osteotomy/adverse effects , Quality of Life/psychology , Rickets/metabolism , Rickets/psychology , Young AdultABSTRACT
The role of the vitamin D receptor (VDR) in maintaining skeletal health appears to be complex and dependent on the physiological context. Global Vdr deletion in a mouse model (Vdr-/-) results in hypocalcemia, secondary hyperparathyroidism and bone features typical of vitamin D-dependent rickets type II. When weanling Vdr-/- mice are fed a diet containing high levels of calcium, phosphorus and lactose, termed the rescue diet, normalisation of serum calcium, phosphate and parathyroid hormone levels results in prevention of rickets at 10 weeks of age. However, 17 week old male Vdr-/- mice, fed the rescue diet, have been reported as osteopenic due to a decrease in bone formation when compared to wild type mice. We now report confirmation of this finding with further data on the effect of the rescue diet on appendicular and axial skeletal structures in male and female Vdr-/- mice at 26 weeks of age compared to Vdr+/- controls. All Vdr-/- mice were normocalcemic with no evidence of any mineralization defect. However, male Vdr-/- mice exhibited significantly reduced mineral in femoral and vertebral bones when compared to control littermate Vdr+/- mice, consistent with the previously reported data. In contrast, 26-week-old female Vdr-/- mice demonstrated significantly increased femoral trabecular bone volume although there was decreased vertebral trabecular bone volume, similar to males, and femoral cortical bone volume was unchanged. Thus, the Vdr-/- mouse model displays sex- and site-specific differences in skeletal structures with long-term feeding of a rescue diet. Although the global Vdr-/- ablation does not permit the determination of skeletal mechanisms producing these differences, these data confirm skeletal changes even when fed the rescue diet.
Subject(s)
Diet/methods , Femur/metabolism , Phenotype , Receptors, Calcitriol/genetics , Rickets/diet therapy , Rickets/metabolism , Animals , Calcium/administration & dosage , Female , Femur/drug effects , Femur/pathology , Gene Expression Profiling , Gene Expression Regulation , Lactose/administration & dosage , Male , Mice , Mice, Knockout , Parathyroid Hormone/genetics , Parathyroid Hormone/metabolism , Phosphates/administration & dosage , Receptors, Calcitriol/deficiency , Rickets/genetics , Rickets/pathology , Sex Factors , Skeleton/pathologyABSTRACT
The metabolism of calcium and bone is controlled by five principal hormones: parathyroid hormone, 1,25-dihydroxyvitamin D, calcitonin, parathyroid hormone-related peptide and fibroblast growth factor 23, some of which have been known for several decades and some of which have only more recently been identified. The stories of the discovery of these hormones have constituted a series of complex journeys that have been undertaken over the past century or so, none of which has yet been completed. The complexities of bone and calcium metabolism have been and remain, to many people, somewhat mysterious and a daunting task to understand. This book is designed to try to unravel those mysteries and present them in an interesting and comprehensible manner.
Subject(s)
Bone and Bones/metabolism , Calcitonin/metabolism , Calcium/metabolism , Fibroblast Growth Factors/metabolism , Parathyroid Hormone-Related Protein/metabolism , Parathyroid Hormone/metabolism , Vitamin D/analogs & derivatives , Bone Density Conservation Agents/therapeutic use , Fibroblast Growth Factor-23 , Humans , Rickets/drug therapy , Rickets/metabolism , Vitamin D/metabolism , Vitamin D/therapeutic useABSTRACT
Rickets is a condition in which there is failure of the normal mineralisation (osteomalacia) of growing bone. Whilst osteomalacia may be present in adults, rickets cannot occur. It is generally caused by a lack of mineral supply, which can either occur as a result of the deficiency of calcium (calciopaenic rickets, now known as parathyroid hormone-dependent rickets) or of phosphate (phosphopaenic rickets, now called FGF23-dependent rickets). Renal disorders may also interfere with the process of mineralisation and cause rickets. Only parathyroid hormone-dependent rickets and distal renal tubular disorders will be discussed in this chapter. The most common cause of rickets is still vitamin D deficiency, which is also responsible for other problems. Disorders of vitamin D metabolism or responsiveness may also cause similar issues. Distal renal tubular acidosis may also be caused by a variety of metabolic errors similar to those of osteoclasts. One form of distal renal tubular acidosis also causes a type of osteopetrosis. This chapter describes these conditions in detail and sets out a logical approach for treatment.
Subject(s)
Acidosis, Renal Tubular/diagnosis , Hypocalcemia/diagnosis , Osteomalacia/diagnosis , Rickets, Hypophosphatemic/diagnosis , Vitamin D Deficiency/diagnosis , Acidosis, Renal Tubular/metabolism , Adult , Calcium/metabolism , Child , Chronic Kidney Disease-Mineral and Bone Disorder/diagnosis , Chronic Kidney Disease-Mineral and Bone Disorder/metabolism , Chronic Kidney Disease-Mineral and Bone Disorder/therapy , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/metabolism , Humans , Hypocalcemia/metabolism , Hypocalcemia/therapy , Osteomalacia/metabolism , Osteomalacia/therapy , Parathyroid Hormone/metabolism , Rickets/diagnosis , Rickets/metabolism , Rickets/therapy , Rickets, Hypophosphatemic/metabolism , Rickets, Hypophosphatemic/therapy , Vitamin D Deficiency/metabolism , Vitamin D Deficiency/therapyABSTRACT
Vitamin D is the sunshine vitamin for good reason. During exposure to sunlight, the UV B photons enter the skin and photolyze 7-dehydrocholesterol to previtamin D3 which in turn is isomerized by the body's temperature to vitamin D3. Most humans have depended on sun for their vitamin D requirement. Skin pigment, sunscreen use, aging, time of day, season and latitude dramatically affect previtamin 13 synthesis. Vitamin D deficiency was thought to have been conquered, but it is now recognized that more than 50% of the world's population is at risk for vitamin D deficiency. This deficiency is in part due to the inadequate fortification of foods with vitamin D and the misconception that a healthy diet contains an adequate amount of vitamin D. Vitamin D deficiency causes growth retardation and rickets in children and will precipitate and exacerbate osteopenia, osteoporosis and increase risk of fracture in adults. The vitamin D deficiency has been associated pandemic with other serious consequences including increased risk of common cancers, autoimmune diseases, infectious diseases and cardiovascular disease. There needs to be a renewed appreciation of the beneficial effect of moderate sunlight for providing all humans with their vitamin D requirement for health.